Mahmoud Zayed, MD
Cardiovascular Disease · Pascagoula, MSNPI 1699790196
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $65,261 of the $102,829 with a category attached, or 63.5%. 51 manufacturers reported payments, led by Boehringer Ingelheim at 32.3% of the total. Reporting peaked in 2022 at $31,798 and has fallen 88.5% since, to $3,664 in 2025. Among cardiovascular disease clinicians in MS with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 790 payments — averaging $130.16 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boehringer Ingelheim$33K
- Shockwave Medical, Inc$21K
- Amgen$18K
- Angiodynamics, Inc.$9K
- Lilly USA, LLC$3K
- Medtronic$3K
- plus $15K from 45 others
What the payments were for
- Speaking & faculty fees$65,26163%
- Travel & lodging$6,4036%
- Food & beverage$22,50222%
- Education$170%
- Gifts$750%
- Other$8,5718%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- JARDIANCE$36,065
- Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter$20,420
- Repatha$17,396
- Auryon Laser System 100-120 Vac$8,474
- Impella$1,201
- Barostim Neo System$548
- AlphaVac$546
- Vascular Lithotripsy$444
- HawkOne$283
- CAMZYOS$255
- XARELTO$248
- AVVIGO Guidance System$238
- FLOWTRIEVER CATHETER, S$235
- IN.PACT Admiral$227
- Alto Abdominal Stent Graft System$180
- GENERAL - STRUCTURAL HEART$142
- VENOVO$142
- SYMPHONY CATHETER$133
- ELIQUIS$125
- FARXIGA$125
How this compares
$102,829 in reported general payments places this provider in the 95th percentile of 144 cardiovascular disease providers in Mississippi.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 417 | $401,854 |
| EntrestoSacubitril/Valsartan | 218 | $246,340 |
| XareltoRivaroxaban | 237 | $211,644 |
| JardianceEmpagliflozin | 136 | $112,764 |
| Repatha SureclickEvolocumab | 65 | $50,182 |
| BrilintaTicagrelor | 41 | $27,946 |
| NexlizetBempedoic Acid/Ezetimibe | 24 | $22,775 |
| VascepaIcosapent Ethyl | 18 | $9,732 |
| Propafenone Hcl ErPropafenone Hcl | 37 | $8,725 |
| Ezetimibe | 376 | $7,919 |
| Metoprolol Succinate | 647 | $7,912 |
| Prasugrel Hcl | 101 | $6,560 |
| Atorvastatin Calcium | 663 | $6,443 |
| Potassium Chloride | 353 | $6,399 |
| Ranolazine ErRanolazine | 53 | $6,143 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $561 | $401,854417 claims |
| NovartisEntresto | $895 | $246,340218 claims |
| Johnson & JohnsonXarelto | $767 | $211,644237 claims |
| Boehringer IngelheimJardiance | $33,170 | $112,764136 claims |
| AstraZenecaBrilinta | $262 | $27,94641 claims |
| Esperion Therapeutics, Inc.Nexlizet | $200 | $22,77524 claims |
| Arbor Pharmaceuticals, Inc.Edarbi | $41 | $5,05213 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 144 cardiovascular disease providers in Mississippi.
Other cardiovascular disease in Pascagoula
- Hugo QuintanaPascagoula$48K
- Ediz TasanPascagoula$42K
- Simon RizkPascagoula$16K
- William PassarelliPascagoula$15K
- Dharmesh PatelSouthaven$1.5M
- Barry BertoletTupelo$469K
- Donny StokesJackson$207K
- James BenslerJackson$64K
- Michael HallJackson$54K
- Lawrence LeaderHattiesburg$40K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.